Aileron Therapeutics Inc. (ALRN) stock plunged during pre-market. Here’s what’s happening?

0
458

Aileron Therapeutics Inc. (NASDAQ: ALRN) stock gained by 8.33% at last close whereas the ALRN stock price declines by 1.71% in the pre-market trading session. Aileron is a chemoprotection oncology firm in clinical development with the goal of significantly changing the chemotherapy process for cancer patients.

>> 7 Top Picks for the Post-Pandemic Economy << 

ALRN stock’ Recent Significant Update

At the European Society of Medical Oncology (ESMO) Virtual Congress 2021, Aileron Therapeutics presented significant clinical data supporting ALRN-6924’s highest potential as a chemoprotective drug. The business reported the final outcome of ALRN-6924’s Phase 1b trial in patients with small cell lung cancer (SCLC) who were receiving second-line topotecan therapy. When compared to historical controls, ALRN-6924 showed ‘triple-play efficacy’ in reducing neutropenia, thrombocytopenia, and anaemia, as well as platelet and red blood cell transfusions.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


Read More

Aileron also announced initial findings from ALRN-6924’s ongoing Phase 1 pharmacology study, which proved 0.3 mg/kg as the ideal dose and confirmed ALRN-6924’s novel p53 biomarker-driven mechanism of action, as well as its pharmacodynamic impacts, such as time to onset, magnitude, and duration.

ALRN-6924 is being developed by Aileron to preserve healthy cells in patients with malignancies that have p53 mutations, reducing or eliminating chemotherapy-induced adverse effects while keeping chemotherapy’s ability to destroy cancer cells. ALRN-6924, a first-in-class MDM2/MDMX dual inhibitor, is meant to stimulate p53 in normal cells, which in response upregulates p21, which in normal cells but not in p53-mutated cancer cells, arrests cell cycle.

Manuel Aivado, President and CEO of Aileron commented,

They’re excited to share the full results of ALRN-6924’s Phase 1b trial in patients with SCLC receiving topotecan, as well as preliminary findings from their current Phase 1 pharmacology investigation in healthy volunteers. Their optimism in ALRN-6924’s best-in-class potential in the burgeoning chemoprotection sector is strengthened by the data presented at ESMO. The goal with their precision medicine method is to make the first selective chemoprotective medication available to all patients with p53-mutated cancer while assuring that treatment is not interrupted. Chemoprotection during chemotherapy, they feel, should eventually be as mandatory as anaesthetic after surgery.

LEAVE A REPLY

Please enter your comment!
Please enter your name here